Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray

被引:0
|
作者
Samalin, Ludovic [1 ]
Mekaoui, Lila [2 ]
De Maricourt, Pierre [3 ]
Sauvaget, Anne [4 ]
Codet, Marie-Alix [5 ]
Gaudre-Wattinne, Emeline [5 ]
Wicart, Clotilde [5 ]
Rotharmel, Maud [6 ]
机构
[1] Univ Clermont Auvergne, Inst Pascal, Dept Psychiat, UMR 6602,CHU Clermont Ferrand,CNRS,Clermont Auverg, Clermont Ferrand, France
[2] St Anne Hosp, GHU Paris Psychiat & Neurosci, Clin Malad Mentales & Encephale, Paris, France
[3] CH Ste Anne, Dept Psychiat, Paris, France
[4] Nantes Univ, CHU Nantes, Movement Interact Performance, MIP, Nantes, France
[5] Janssen Cilag, Med Affairs, Issy Les Moulineaux, France
[6] Rouvray Hosp Ctr, Univ Dept Psychiat, Inst Psychiat, Therapeut Ctr Excellence, Sotteville Les Rouen, France
关键词
Antidepressant; esketamine; treatment-resistant depression; real-world experience; clinical profile; SAFETY; EFFICACY;
D O I
10.1080/13651501.2024.2398788
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
ObjectiveESKALE is a French, multicentre, observational study of adults with treatment-resistant depression (TRD) treated with esketamine. This interim analysis describes baseline demographic and clinical characteristic evolution in patients included and treated from early access program to post-marketing launch.MethodsData were collected from medical records and included patient characteristics, disease history at esketamine initiation, use of neurostimulation, the patient's care pathway, and the number of antidepressant treatment lines prescribed prior to esketamine initiation. Descriptive statistics were used for each cohort: the early access program 'Temporary Authorisation for Use' (ATU), post-ATU, and post-launch cohorts.ResultsThe overall ESKALE cohort (N = 160 included; n = 157 treated with esketamine; average age 49.0 years; 66.2% female) demonstrated moderate-to-severe depression according to clinical assessment and a mean Montgomery-& Aring;sberg Depression Rating Scale score of 32.6 (8.0); however, severity, subtype, and comorbidities were heterogeneous across the cohorts. Earlier use of esketamine and prior to alternative treatments occurred during the later cohorts.ConclusionThese findings demonstrated a high burden of TRD in these patients and that esketamine is used in TRD treatment regardless of their disease severity, subtype, or existing comorbidities. These results also suggest that esketamine is potentially a clinically useful alternative treatment, particularly with healthcare professionals gaining greater familiarity with and easier access to esketamine. ESKALE is a long-term, French, multicentre, observational study based on secondary data in adult patients with treatment-resistant depression (TRD) who initiated esketamine treatment in one of three mutually exclusive cohorts: the Temporary Authorisation for Use (ATU), post-ATU, and post-launch cohorts.ESKALE is one of the largest European real-world studies investigating the profiles of more than 150 patients and their treatment with esketamine before and after marketing authorisation.A majority of patients had moderate to severe TRD, with multiple treatment failures with medications and/or neurostimulation prior to esketamine initiation.Esketamine nasal spray administration was undertaken more frequently in an outpatient setting, with the post-administration period monitoring being undertaken mostly by nurses.Esketamine was used in patients with TRD in real-world conditions regardless of their disease severity and subtype or existing comorbidities.These results highlight both the need for an effective treatment for TRD and the adoption of esketamine by multidisciplinary teams that are involved in esketamine prescription and administration.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] In treatment-resistant depression, adding esketamine nasal spray to an oral antidepressant improved symptoms at 28
    Pal, Hemraj
    ANNALS OF INTERNAL MEDICINE, 2019, 171 (06) : JC33 - JC33
  • [32] Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression
    Perez-Ruixo, Carlos
    Rossenu, Stefaan
    Zannikos, Peter
    Nandy, Partha
    Singh, Jaskaran
    Drevets, Wayne C.
    Perez-Ruixo, Juan Jose
    CLINICAL PHARMACOKINETICS, 2021, 60 (04) : 501 - 516
  • [33] NEW NASAL SPRAY FOR TREATMENT-RESISTANT DEPRESSION
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2019, 119 (07) : 22 - 23
  • [34] Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA
    Jha, Manish K.
    Zhdanava, Maryia
    Shah, Aditi
    Voegel, Arthur
    Tardif-Samson, Anabelle
    Pilon, Dominic
    Joshi, Kruti
    DRUGS-REAL WORLD OUTCOMES, 2025, 12 (01) : 35 - 43
  • [35] Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
    Ahmed, Nahida Nayaz
    Albishi, Faisal
    Khan, Suhail A.
    Alsayegh, Ammar
    Stip, Emmanuel
    Makhoul, Samer
    MIDDLE EAST CURRENT PSYCHIATRY-MECPSYCH, 2023, 30 (01):
  • [36] Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
    Nahida Nayaz Ahmed
    Faisal Albishi
    Suhail A. Khan
    Ammar Alsayegh
    Emmanuel Stip
    Samer Makhoul
    Middle East Current Psychiatry, 30
  • [37] Compassionate use of esketamine nasal spray in patients ≥65 years old with treatment-resistant depression: a descriptive multicenter study
    Fuertes-Saiz, A.
    Elvira Cruanes, V.
    Etxeandia-Pradera, J. I.
    Martinez Pastor, C.
    Rosello-Molina, V.
    Barberan-Navalon, M.
    Avellon Juarez, V.
    Mora-Marin, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 : S167 - S167
  • [38] Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States
    Clemens, Kristin
    Zhdanava, Maryia
    Teeple, Amanda
    Voegel, Arthur
    Joshi, Kruti
    Shah, Aditi
    Chen, Cindy
    Pilon, Dominic
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2025, 31 (01): : 101 - 111
  • [39] Sleep disturbance and efficacy of esketamine nasal spray in patients with treatment-resistant depression: findings from randomized, controlled trials
    Borentain, S.
    Williamson, D.
    Turkoz, I.
    Popova, V.
    McCall, W. V.
    Mathews, M.
    Wiegand, F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 : S267 - S268
  • [40] Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies
    Morrison, Randall L.
    Singh, Jaskaran
    Daly, Ella
    Fedgchin, Maggie
    Ochs-Ross, Rachel
    Karcher, Keith
    Lane, Rosanne
    Cooper, Kim
    Sanacora, Gerard
    Maruff, Paul
    Drevets, Wayne C.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2024, 27 (11):